Purpose: To develop a localized rat knee streptococcal peptidoglycanpolysaccharide (PGPS) model of osteoarthritis and to evaluate the efficacy of single intra-articular (IA) doses of FX006, a sustained release formulation of triamcinolone acetonide (TCA) in poly(lactic-co-glycolic acid) (PLGA) microspheres and Kenalog-40Ò, a crystalline suspension of TCA. Methods: The PGPS model was modified to induce localized knee osteoarthritis with synovitis and assess prolonged duration of efficacy. Synovitis was induced in the right knees of 75 rats with injection of PGPS two weeks prior to treatment with a single IA injection of FX006 on Day 1 (TCA in PLGA microspheres), KenalogÒ, or vehicle. Three flares of synovitis were induced with tail vein injections of PGPS on Days 1 (2.5 hours after IA dosing), and subsequently on Days 14 and 28 (with no further dosing with treatments). FX006 was administered at doses of 0.28, 0.12 or 0.03 mg TCA and KenalogÒ at 0.06 mg (which provides overall TCA exposure comparable to FX006 at 0.28 mg; AUCw 350 ng.hr/mL). Differences in weightbearing and gait (as a measure of knee pain), histopathology, pharmacodynamics (serum corticosterone) and plasma pharmacokinetics (PK) were characterized. reactivation. FX006 demonstrated dose-dependence in the magnitude and duration of effect (data not shown). Though the total amount of TCA in the high dose of FX006 is approximately 5X the amount in the KenalogÒ injection, the C max at this dose was 1/10 th , and systemic exposure comparable to that provided by the KenalogÒ injection (the C max in KenalogÒ-treated animals of 17 ng/mL was also greater than that reported following the labeled 40 mg IA dose in patients). Histopathological evaluation of the knees taken at the end of the study demonstrated dose dependent, statistically significant improvement by FX006 in the composite histological score and each component score (inflammation, pannus, cartilage damage and bone resorption) with scores approximating normal tissue architecture at the high and mid-dose of FX006. All treatment groups had similar corticosterone levels at baseline that were initially inhibited following both KenalogÒ and FX006 treatment, but recovered by Day 14.
Purpose: To develop a localized rat knee streptococcal peptidoglycanpolysaccharide (PGPS) model of osteoarthritis and to evaluate the efficacy of single intra-articular (IA) doses of FX006, a sustained release formulation of triamcinolone acetonide (TCA) in poly(lactic-co-glycolic acid) (PLGA) microspheres and Kenalog-40Ò, a crystalline suspension of TCA. Methods: The PGPS model was modified to induce localized knee osteoarthritis with synovitis and assess prolonged duration of efficacy. Synovitis was induced in the right knees of 75 rats with injection of PGPS two weeks prior to treatment with a single IA injection of FX006 on Day 1 (TCA in PLGA microspheres), KenalogÒ, or vehicle. Three flares of synovitis were induced with tail vein injections of PGPS on Days 1 (2.5 hours after IA dosing), and subsequently on Days 14 and 28 (with no further dosing with treatments). FX006 was administered at doses of 0.28, 0.12 or 0.03 mg TCA and KenalogÒ at 0.06 mg (which provides overall TCA exposure comparable to FX006 at 0.28 mg; AUCw 350 ng.hr/mL). Differences in weightbearing and gait (as a measure of knee pain), histopathology, pharmacodynamics (serum corticosterone) and plasma pharmacokinetics (PK) were characterized. Results: As shown in the Figure, upon Introduction: Post-operative thrombo-prophylaxis is believed to reduce the perioperative risk for patients following total hip and knee arthroplasty. The non-adherence rate in the literature for patients completing their prescribed course of traditional thrombo-prophylaxis varies from 5-40%. Newer oral thrombo-prophylatic agents are now available (factor Xa inhibitors), however their patient compliance rate is unknown. This study compares the compliance rate of a prescribed oral factor Xa inhibitor, RivaroxabanÒ, for the thrombo-prophylaxis of post-operative hip and knee arthroplasty patients and compares it to the established literature compliance rates of other modalities. The non-adherent patients were then subgroup analysed to examine for non-compliant patient risk factors. Methods: Since January 2010, an on going prospective database for all total joint replacement surgeries has followed patients treated with thromboprophylaxis post-operatively. As a standard of care, a self-administered questionnaire is recorded at the six-week mark. This includes information about the medication used for thrombo-prophylaxis, the prescription administration, compliance and complications from therapy. The compliance of their prescribed fourteen-day therapy was then calculated and compared to the published literature compliance rates of other thromboprophylaxis agents. A sub-group analysis was then undertaken of the nonadherence (NA) group. Results: A total of 1789 patients (1343 total knees and 947 total hips) received a prescription for Rivaroxaban post-operatively. Of these, 53 (3.0%) did not complete their six-week follow up questionnaire. Another 52 (2.9%) stated they did not complete the entire course of prescribed therapy. The overall compliance rate of those given a prescription is 97.1%. If we assume all those lost to follow-up did not complete their prescribed course, the compliance drops to 94.1%, leaving a non-adherence (NA) rate of 5.9% for Rivaroxaban. The group of stated non-adherent patients were more likely to be female (71.2% vs 60.1%, p¼0.03), and were trending to have a higher BMI (30.6 vs 28.9, p¼0.08). Age was not a factor for either group. Four patients who were NA encountered bleeding complications, compared to 18 in the compliant group (7.5% vs 1.1% p¼0.01). Discussion: This study demonstrates that patients are more likely to complete a thrombo-prophylaxis regime on an oral Factor Xa inhibitor than other therapies. The stated NA rate of prescribed Rivaroxaban is 2.9%. Assuming all those lost to follow-up were non-adherent, the calculated overall NA rate would be 5.9%. This compares favourably to the nonadherence rates of injectable low molecular weight, which has multiple published series demonstrating NA of 5-40%, and most recently, a large multi-center series of 1315 patients showing a NA of 20.8%. This study demonstrates that the prescription of rivaroxaban affords a superior patient compliance compared with subcutaneous LMWH. Purpose: The aim of this study was to investigate the clinical consequences and the levels of chemokines in OA patients treated either with chondroitin sulphate (CS) or paracetamol.
Methods: OA patients were treated with CS (800 mg/day) or paracetamol (4 g/day) for 6 month. Clinical examination was performed at baseline, and after 1.5, 6 and 9 months of treatment, with collection of plasma and synovial fluid. The clinical examination included measurement of the overflow, hypertrophy and vascularisation of the synovia as well as functional study of the articulation (with Lequesne and EVA index). The levels of CXCL16, fractalkine/CX 3 CL1, MCP-1/CCL-2, RANTES/CCL5 and GRO-a/ CXCL1 were determined by ELISA in the plasma and synovial samples collected. The statistical analysis was performed with SPSS package. We performed two different analyses. In the first one, we studied the difference between the levels of the chemokine between each time and the baseline. We performed this analysis in separate with the paracetamol group and chondroitin one. For this comparison we used a non parametric test (Wilcoxon 2 related samples test). We performed a second analysis in order to analyze if there were differences in the chemokine levels over time, depending on the treatment received. For this analysis an independent sample t-test was performed.
Results: Improvements in the clinical signs of inflammation were detected after 6-9 months after CS treatment of OA patients. The comparison of the levels of each chemokine at the different times studied versus the baseline, indicated us that these effects were accompanied by a significant reduction in the synovial levels of MCP-1 at 6 month (p¼0.05), whereas in the paracetamol group there was a significant increased level of RANTES (p¼0.035). In plasma, only MCP-1 concentration was significant diminished (p¼0.023) by CS administration. To study in global the answer to the treatments, we perform a comparison between the effect of each drug to the levels of each chemokine. This analysis showed us that there were significant differences between the response to the treatment in MCP-1, 6 month after treatment (p¼0.016), and in fractalkine, 9 month after treatment (p¼0.036). In both cases the treatment with chondroitin showed a diminution of the levels of the chemokines, while paracetamol didn't affect in the case of MCP-1 or even increased in the case of fractalkine. All these data show that chemokine attraction of macrophage, T-cell, eosinophil and basophil is reduced with a 6 month treatment with chondroitin. Conclusions: These results suggest that CS sulphate may represent an adequate drug to reduce the inflammation associated to the OA process.
LINKING AN ADAMTS5-SPECIFIC THERAPEUTIC MONOCLONAL ANTIBODY TO A SENSITIVE BIOCHEMICAL MARKER OF TARGET ENGAGEMENT AND ACTIVITY FOR POTENTIAL APPLICATION AS A COMPANION DIAGNOSTIC
J. Larkin. GlaxoSmithKline, King of Prussia, PA, USA Purpose: The goal of co-developing a companion diagnostic alongside a therapeutic has distinct advantages for drug development and has recently been suggested by some regulatory agencies to be the preferred scenario for future approvals. The ability to identify patient subsets most likely to respond to and benefit from a treatment not only allows for focused stratification and reduced development costs, but also has the potential to reduce healthcare expenditures through defined treat/nontreat guidelines. This scenario is especially useful in the context of osteoarthritis (OA) where the sheer patient numbers, multifactorial etiology and unmet need of the patient population dictates an effective stratified approach to clinical development and market acceptance. Methods: The Target: ADAMTS5 -A Disintegrin And Metalloprotease with ThromboSpondin motifs 5, is a key protease involved in degradation of cartilage (aggrecan). Activity is upregulated in osteoarthritis1,2 and inflammatory arthritic1,3 diseases leading to impaired joint function and disability. Genetic loss of function is associated with cartilage protection in preclinical disease models4-6. The Therapeutic: A high affinity humanized mAb that specifically binds and neutralizes ADAMTS5, engages the target in vivo (cartilage), inhibits cartilage degradation with extended duration in human OA cartilage explant studies, and dose dependently modulates circulating ARGS neoepitope levels following systemic administration in cynomolgus monkeys, supporting its potential as an OA disease modifying drug. Results: The Diagnostic: ARGS Neoepitope -A sensitive immunoassay capable of quantifying a specific 'signature' of ADAMTS5-mediated cleavage of aggrecan in serum, plasma, urine and synovial fluid with applications for patient selection, monitoring response and potentially efficacy. Conclusions: The Therapeutic Profile: By delaying structural disease progression, and stabilizing or improving pain and/or function, it will fill a large unmet need in joint diseases. As a chronic therapy, the safety profile will be suitable for long term administration. Conclusions: These results show that the essential oil of E. duriaei subsp. juresianum reduces both IL-1-induced NF-kB and MAPK activation, although it is more effective towards inhibition of NF-kB and JNK. Taken together, the results obtained suggest that this essential oil contains compound(s) that may present anti-inflammatory and anti-catabolic properties, and thus, potential disease-modifying anti-osteoarthritic activity. Future work will focus on the fractionation and identification of those compounds followed by further pharmacologic characterization. 
